KCNE4-dependent modulation of Kv1.3 pharmacology.

Abstract in brief

• The study explores how the ancillary subunit KCNE4 influences the pharmacology of the Kv13 potassium channel, which is a target for treating autoimmune and inflammatory conditions, by examining its effects on drug binding and channel behavior.
• KCNE4 decreases Kv13 surface levels and increases channel inactivation in leukocytes, affecting how the channel responds to drugs like margatoxin and Psora4, which bind from outside and inside the cell, respectively.
• The findings suggest that KCNE4 changes the internal structure of Kv13 without affecting drug affinity, highlighting the importance of considering different Kv13-KCNE4 configurations in the development of targeted therapies for immune-related diseases.]